January has you setting ambitious targets again - but are they the right targets?
Whether you're leading a team or building a business, most high-performers are running on inherited success frameworks - the same achievement patterns that worked at school or in more junior roles. But the systems that got you here won't get you where you're trying to go.
Showcasing Cambridge & London life science, biotech, deeptech & techbio ventures, offering investors early insight, and emerging innovation.
For many in the global life sciences industry, JPM Week at the start of the year in San Francisco is seen a sone of those pivotal weeks that sets the tone for the forthcoming months as investors, companies, advisors and policymakers all converge at scale around a plethora of events and activities.
One Nucleus will be delighted to be supporting our members in their endeavours to connect with their peers and instigate the deal flow that will shape their 2026. Below is a summary of the opportunities for our members:
RESI JPM
The UK has the potential to unlock £8[1] in socio-economic returns for every £1 spent on preventive healthcare, according to a new health report by Deloitte.
Building and nurturing relationships is an essential part of successful business partnerships. BIO-Europe Spring brings together over 3,700 leading executives from around the world, hosting more than 20,000 partnering meetings between biotech companies, startups and academia with pharma companies and forward-thinking investors.
Through partnership with One Nucleus partners, EBD Group, One Nucleus looks forward to supporting our members again this year at BIO-Europe Spring 2025.
Cutting-edge product for stem cell research and human embryo modelling
Amsbio reports that its iMatrix-511 recombinant laminin product has been cited in a recent paper** from researchers at the Stanford University School of Medicine, Stanford, CA, USA as a pivotal tool for stem cell culture and blastoid formation.
Become a mentor on Beacon’s Patient Group Mentoring Programme and make a real difference to the rare disease community!
Mentees need support across a wide range of areas, from charity management and fundraising to communications, life sciences and more.
You don’t need a background in rare diseases to have something valuable to offer.
As a mentor, you will:
• Be paired with a rare disease patient group leader for a 12-month partnership
• Grow your leadership skills and aid your professional development
Enedra Therapeutics (Enedra), a pioneering biotechnology company focused on developing novel treatments for genetically heterogeneous cancers, today announced the appointment of Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors. His appointment comes as Enedra prepares to initiate its seed phase fundraising round.
[Letchworth Garden City, December 2025] – DLRC Group has today announced its certification as a B Corporation (or B Corp), joining a growing movement of companies that are reinventing business for the benefit of all people and our shared planet. Verified by B Lab, the not-for-profit behind the B Corp movement, the achievement demonstrates that DLRC Group meets high standards of social and environmental performance, transparency, and accountability alongside a commitment to goals beyond shareholder value.
We are seeking an enthusiastic and talented Postdoctoral Research Scientist to join the David group at the Babraham Institute in Cambridge. Our overarching goal is to discover mechanisms that promote healthy ageing and alleviate age-related diseases such as Alzheimer’s disease. Our group has uncovered mechanisms that prevent age-related protein aggregation, a major contributor to functional decline. Notably, we discovered a proteostasis network that safeguards proteins from aggregation in the extracellular space in C.